Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
Completes SYMON-II clinical study enrollment and advances clinical validation activities.Achieves critical manufacturing milestone ahead of contractual deadline, strengthening supply chain and commercialization readiness.Targets FDA 510(k) …
Weiterlesen »